SCHEMBL2465896

SCHEMBL2465896

CC(=O)Nc1ccc(Cc2noc(-c3cc(Br)ccc3OCC(=O)O)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.46
HTR2C P28335 1/20 0.46
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
PTGDR2 Q9Y5Y4 5/20 0.43
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PTGER1 P34995 2/20 0.39
AGPAT2 O15120 1/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463039 0.88 PTGDR2 (0.47) PRMT5WDR77PTGDR2MAPTLMNA
SCHEMBL1996328 0.86 PTGDR2 (0.56) PRMT5WDR77PTGDR2LMNASMN1; SMN2
SCHEMBL2464504 0.86 MAPT (0.50) PTGDR2MAPTLMNASMN1; SMN2PTGER1
SCHEMBL1995885 0.85 PTGDR2 (0.47) PRMT5WDR77PTGDR2LMNASMN1; SMN2
SCHEMBL1993270 0.85 ALDH1A1 (0.51) PRMT5WDR77PTGDR2ALDH1A1HTT
SCHEMBL2462176 0.84 LMNA (0.59) PRMT5WDR77PTGDR2MAPTGAA
SCHEMBL27829944 0.83 HTR1A (0.51) HTR1AHTR2CMAPTTP53SMN1; SMN2
SCHEMBL2465338 0.82 NMT1 (0.47) PRMT5WDR77PTGDR2MAPTLMNA
SCHEMBL2467718 0.82 PTGDR2 (0.46) PRMT5WDR77PTGDR2LMNASMN1; SMN2
SCHEMBL2466354 0.82 PTGDR2 (0.47) PRMT5WDR77PTGDR2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269763-A1 CRTH2 receptor ligands for medicinal uses 7TM PHARMA A/S (DK) 2011-11-03 US disclosed
US-20110269763-A1 CRTH2 receptor ligands for medicinal uses 7TM PHARMA A/S (DK) 2011-11-03 US disclosed
US-8022063-B2 CRTH2 receptor ligands for medicinal uses 7TM PHARMA A/S (DK) 2011-09-20 US disclosed
US-8022063-B2 CRTH2 receptor ligands for medicinal uses 7TM PHARMA A/S (DK) 2011-09-20 US disclosed
US-8022063-B2 CRTH2 receptor ligands for medicinal uses 7TM PHARMA A/S (DK) 2011-09-20 US disclosed
EP-2336113-A1 CRTH2 Receptor Ligands for Medical Use 7TM Pharma A/S (DK) 2011-06-22 EP disclosed
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses 7TM PHARMA A/S (DK) 2009-04-16 US disclosed
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses 7TM PHARMA A/S (DK) 2009-04-16 US disclosed
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses 7TM PHARMA A/S (DK) 2009-04-16 US disclosed
EP-1758579-A1 CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115382-A1 CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses HRH1, HRH2, HRH3 HTR1A 377/4885HTR2C 307/4885PRMT5 2686/4885
US-20110269763-A1 CRTH2 receptor ligands for medicinal uses HRH1, HRH2, HRH4 HTR1A 220/4885HTR2C 184/4885PRMT5 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.